Copper histidine subcutaneous - Cyprium Therapeutics

Drug Profile

Copper histidine subcutaneous - Cyprium Therapeutics

Alternative Names: CUTX 101

Latest Information Update: 04 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institute of Child Health and Human Development
  • Developer Cyprium Therapeutics; National Institute of Child Health and Human Development
  • Class Heavy metals
  • Mechanism of Action Heavy metal replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Menkes kinky hair syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Menkes kinky hair syndrome

Most Recent Events

  • 02 Jul 2018 Copper histidine subcutaneous - Cyprium Therapeutics receives Fast Track designation for Menkes kinky hair syndrome [SC,Injection] in USA
  • 14 Mar 2017 Cyprium Therapeutics establishes CRADA with National Institute of Child Health and Human Development for the development of copper histidine subcutaneous in Menkes disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top